Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

Published:2022-06 Issue:6 Volume:10 Page:407-417
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Battelino Tadej,Bergenstal Richard M,Rodríguez Angel,Fernández Landó Laura,Bray Ross,Tong Zhentao,Brown Katelyn

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference26 articles.

1. Time in range: a new parameter to evaluate blood glucose control in patients with diabetes;Gabbay;Diabetol Metab Syndr,2020

2. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range;Battelino;Diabetes Care,2019

3. Continuous glucose monitoring sensors for diabetes management: a review of technologies and applications;Cappon;Diabetes Metab J,2019

4. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial;Frías;Lancet,2018

5. International consensus on use of continuous glucose monitoring;Danne;Diabetes Care,2017

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies;Diseases;2024-09-05

2. Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials;Biomedicines;2024-08-23

3. Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment;Endocrine Practice;2024-08

4. Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1‐year real‐world assessment;Diabetes, Obesity and Metabolism;2024-07-15

5. Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence;Frontiers in Endocrinology;2024-06-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3